Zhejiang Shouxiangu Pharmaceutical Co Ltd
SSE:603896
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
18.81
37.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Income from Continuing Operations
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhejiang Shouxiangu Pharmaceutical Co Ltd
SSE:603896
|
Income from Continuing Operations
¥233.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Hengan International Group Company Ltd
HKEX:1044
|
Income from Continuing Operations
¥3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
|
Proya Cosmetics Co Ltd
SSE:603605
|
Income from Continuing Operations
¥1.5B
|
CAGR 3-Years
41%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
|
Income from Continuing Operations
¥759.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
By-health Co Ltd
SZSE:300146
|
Income from Continuing Operations
¥1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
Income from Continuing Operations
¥1.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Glance View
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the breeding, cultivation, processing, and sale of Chinese herbal pieces and health food. The company is headquartered in Jinhua, Zhejiang and currently employs 1,026 full-time employees. The company went IPO on 2017-05-10. The firm's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The firm mainly operates its businesses in domestic markets through wholesaling and direct sales.
See Also
What is Zhejiang Shouxiangu Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
233.8m
CNY
Based on the financial report for Sep 30, 2024, Zhejiang Shouxiangu Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 233.8m CNY.
What is Zhejiang Shouxiangu Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
17%
Over the last year, the Income from Continuing Operations growth was -18%. The average annual Income from Continuing Operations growth rates for Zhejiang Shouxiangu Pharmaceutical Co Ltd have been 11% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
